Dataset Information


MTOR inhibitors synergistically induce regression, reversal of gene expression and autophagy in hepatocellular carcinoma

ABSTRACT: The mTOR-allosteric inhibitor, RAD001, in combination with a PI3K/mTOR ATP-site competitive inhibitor, BEZ235, causes gene reprogramming, autophagy and tumor regression, in a mouse model approximating human HCC with poor prognosis, leading to an investigator Phase 1B-2 clinical trial. Comparative study of total RNA obtained from normal and tumor liver tissue under RAD001, BEZ235, or RAD001 + BEZ235.

ORGANISM(S): Mus musculus  

SUBMITTER: Michel Maira   Liu Manway  Jongsun Park  Larissa S Carnevalli  Manway Liu  Paul S Mischel  Sara C Kozma  Snorri S Thorgeirsson  Jesper B Andersen  Hala E Thomas  Tomoo Matsutani  Bruce J Aronow  George Thomas  Akio Iwanami  Kazuhiro Tanaka  Carol A Mercer  Elizabeth A Conner 

PROVIDER: E-GEOD-37129 | ArrayExpress | 2012-07-11



altmetric image


Hepatocellular carcinoma (HCC) affects more than half a million people worldwide and is the third most common cause of cancer deaths. Because mammalian target of rapamycin (mTOR) signaling is up-regulated in 50% of HCCs, we compared the effects of the U.S. Food and Drug Administration-approved mTOR-allosteric inhibitor, RAD001, with a new-generation phosphatidylinositol 3-kinase/mTOR adenosine triphosphate-site competitive inhibitor, BEZ235. Unexpectedly, the two drugs acted synergistically in i  ...[more]

Similar Datasets

2012-07-12 | GSE37129 | GEO
2008-06-15 | E-GEOD-6610 | ArrayExpress
2017-05-24 | PXD006263 | Pride
2012-03-13 | E-GEOD-28992 | ArrayExpress
2011-04-25 | E-GEOD-28818 | ArrayExpress
2011-08-30 | E-GEOD-25172 | ArrayExpress
2004-05-17 | GSE1413 | GEO
2015-08-27 | E-MTAB-2882 | ArrayExpress
| GSE83401 | GEO
2011-09-13 | E-GEOD-25173 | ArrayExpress